Roche Pharmaceutical Development and Sales Overview

Hemophilia A franchise: Hemlibra new global standard of care 36% US/EU-5 patient share reached Roche CHFM 1,200 1,000 800 600 >500% 400 200 +57% YoY CER growth +23% . +37% Hemophilia Q3 update • >18,000 patients treated globally • Hemlibra continues to penetrate across all approved patient segments • 2nd generation FIXa x FX bi-specific (NXT007) to be taken into Roche clinical development Outlook 2022 • US/EU: Further patient share gains in non-inhibitors • EU: Label expansion to include mild/moderate patients • (HAVEN 6) expected ⚫ Ph III (HAVEN 7) in infants (0-1 year) submitted for presentation at ASH 2022 0 Q3 19 Q3 20 Q3 21 Q3 22 US Europe International Japan CER=Constant Exchange Rates 23

View entire presentation